Literature DB >> 25824218

Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice.

Alexandra J Burton1, Steeve Giguère2, Londa J Berghaus1, Mary K Hondalus3.   

Abstract

Treatment of mice with the combination of clarithromycin with rifampin resulted in a significantly lower number of Rhodococcus equi CFU in the organs of mice than treatment with either drug alone or placebo. There was no significant difference in the number of R. equi CFU between mice treated with clarithromycin monotherapy, rifampin monotherapy, or placebo. The combination of clarithromycin with rifampin conferred a clear advantage over either drug as monotherapy in this model of chronic R. equi infection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25824218      PMCID: PMC4432177          DOI: 10.1128/AAC.04941-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia.

Authors:  C J Hillidge
Journal:  Vet Microbiol       Date:  1987-08       Impact factor: 3.293

2.  In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials.

Authors:  Stephanie S Jacks; Steeve Giguère; An Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  In-vitro antimicrobial susceptibility of Rhodococcus equi.

Authors:  P Nordmann; E Ronco
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

5.  Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection.

Authors:  R J Wallace; B A Brown; D E Griffith; W Girard; K Tanaka
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

6.  Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia.

Authors:  Steeve Giguère; Stephanie Jacks; Gregory D Roberts; Jorge Hernandez; Maureen T Long; Christina Ellis
Journal:  J Vet Intern Med       Date:  2004 Jul-Aug       Impact factor: 3.333

7.  Rhodococcus equi pneumonia in 48 foals: response to antimicrobial therapy.

Authors:  C R Sweeney; R W Sweeney; T J Divers
Journal:  Vet Microbiol       Date:  1987-08       Impact factor: 3.293

8.  Deletion of vapA encoding Virulence Associated Protein A attenuates the intracellular actinomycete Rhodococcus equi.

Authors:  Shruti Jain; Barry R Bloom; Mary K Hondalus
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

9.  Differential efficacy of clarithromycin in lung versus thigh infection models.

Authors:  Dana Maglio; Blair Capitano; Mary Anne Banevicius; Qiuming Geng; Charles H Nightingale; David P Nicolau
Journal:  Chemotherapy       Date:  2004-06       Impact factor: 2.544

10.  Therapy of Rhodococcus equi disseminated infections in nude mice.

Authors:  P Nordmann; J J Kerestedjian; E Ronco
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

View more
  2 in total

1.  Rhodoccocus Equi Pneumonia and Paradoxical Immune Reconstitution Inflammatory Syndrome in a Patient with Acquired Immune Deficiency Syndrome (AIDS).

Authors:  Ritika Zijoo; Ahmed Dirweesh; Nigahus Karabulut
Journal:  Am J Case Rep       Date:  2017-01-19

2.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.